Office of Technology Management
University Center Tower (UCT)
7000 Fannin Street, Suite 720
Houston, Texas 77030
Phone: (+1) 713-500-3369
Fax: (+1) 713-500-0331
Activating mutations of KRAS are known to occur in about 25% of all human cancers. Currently, there are no drugs that can directly act on mutated KRAS to stop its cancer causing activities. As a result, KRAS-related cancers, which include some of the deadliest, such as pancreatic cancer, remain untreatable. Finding a direct inhibitor of KRAS remains a major challenge in the search for cancer therapy. Technology:Dr.Gorfe at the University of Texas Health Science Center Houston has used a structure based computational ligand design approach followed by biophysical and cell biological experi...
With the availability of genotyping data of very large samples, there is an increasing need for tools that can efficiently identify genetic relationships among all individuals in the sample. One fundamental measure of genetic relationship of a pair of individuals is identity by descent (lBD), chromosomal segments that are shared among two individuals due to common ancestry. However, the efficient identification of lBD segments among a large number of genotyped individuals is a challenging computational problem. Some methods, such as GERMLINE, use fast dictionary lookup of short seed sequence m...
Faculty members at the University of Texas Health Science Center at Houston have developed a novel chemical linker for constructing antibody-drug conjugates (ADCs). While traditional ADC linkers can only load a single payload molecule, the developed linker has the ability to load two identical or different drug payloads. Doubling the number of payloads increases the drug-to antibody ratio which can lead to enhanced potency in cell viability assays (as shown in animal model experiments). The novel linker system provides the opportunity to revisit payloads that are mechanistically attractive; pa...
NCATS STTR Funding Opportunities Open for Academic Researchers & Entrepreneur
The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health invites researchers at academic institutions to apply for Small Business Technology Transfer (STTR) support to commercialize innovations. The next application deadline is Sept. 5, 2018, 5:00 p.m. local time. STTR programs are one of the largest sources of early-stage technology financing in the U.S.
TMCx Open 2018 Medical Device Cohort Application
Deadline: May 14, 2018
TMCx lowers barriers of access to the world's largest medical center, allowing startups to leverage our expansive network of advisors from the 21 Texas Medical Center hospitals and our tailored curriculum to clinically validate and find product-market fit for their solutions.
The TMCx Medical Device 2017 cohort of 19 startups raised $26M and had over 43 engagements with potentials customers in the form of pilots and agreements over the course of our three-month program.